Characterization of the E3 ligase KCMF1 as a ZZ/N-recognin of the autophagic Arg/N-degron pathway
Methods in Enzymology · 2025
DOI: 10.1016/bs.mie.2025.06.010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Methods in Enzymology, 2025. Verfasst von Ji Su Lee und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, College of Medicine, Seoul National University, Seoul, Republic of Korea; College of Medicine, Cellular Degradatio…. Hauptthemen laut MEDLINE: Autophagy, Arginine, Ubiquitin-Protein Ligases. Die Arbeit nennt 63 Literaturangaben.
Abstract (Originalsprache)
In the Arg/N-degron pathway, Arg/N-degrons share the N-terminal (Nt) arginine (Nt-Arg) residue and hydrophobic amino acid residues that can be generated through Nt-arginylation by ATE1-encoded R-transferases (EC 2.3.2). In the ubiquitin-proteasome system (UPS), N-degrons are recognized by the UBR box of N-recognins that facilitate ubiquitination and proteasomal degradation. Arg/N-degrons also modulate the lysosomal degradation of proteins and other biomaterials via the autophagy-lysosome system (ALS). In this autophagic process, N-degrons function through their recognition by the ZZ-type zinc finger domain of the N-recognin p62/SQSTM1-1/Sequestosome-1. Recently, we identified the E3 ligase KCMF1 (potassium channel modulatory factor 1) as an autophagic N-recognin at the crossroads of the UPS and ALS. KCMF1 binds Nt-Arg and structurally related Nt-motifs through its ZZ domain, a structural equivalent to the ZZ domain of p62 as well as the UBR box of N-recognins. Under oxidative stress such as prolonged hypoxia where protein aggregates accumulate, the cysteine (Cys) residue at position 2 is Nt-exposed through the Nt-methionine (Nt-Met) excision and undergoes chemical oxidation into Cys sulfonic acid (CysO3) followed by Nt-arginylation. The resulting Arg-CysO3 N-degron binds KCMF1 to induce the assembly of lysine 63 (Lys63)-linked Ub chains, to which p62-type autophagic receptors bind via their Ub-associated (UBA) domain for autophagic degradation. Through this collaboration between the UPS and ALS, Arg-CysO3 N-degrons contribute the degradation of harmful protein species generated under cellular stresses. Here, we describe biochemical assays to characterize KCMF1 as an emerging N-recognin, including its interaction with synthetic N-degrons and its activity to undergo self-polymerization stimulated by N-degrons.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Sciences, College of Medicine, Seoul National University, Seoul, Republic of Korea; College of Medicine, Cellular Degradation Biology Center, Seoul National University, Seoul, Republic of Korea.
- College of Medicine, Cellular Degradation Biology Center, Seoul National University, Seoul, Republic of Korea. Electronic address: dasubin@snu.ac.kr.
- Department of Biomedical Sciences, College of Medicine, Seoul National University, Seoul, Republic of Korea; College of Medicine, Cellular Degradation Biology Center, Seoul National University, Seoul, Republic of Korea;…
- College of Medicine, Cellular Degradation Biology Center, Seoul National University, Seoul, Republic of Korea; AUTOTAC Bio Inc., Seoul, Republic of Korea. Electronic address: changhoon.ji@snu.ac.kr.
Zitieren
APA
Lee, J. S., Lee, M. J., Kim, S. B., Kwon, Y. T., & Ji, C. H. (2025). Characterization of the E3 ligase KCMF1 as a ZZ/N-recognin of the autophagic Arg/N-degron pathway. Methods in Enzymology. https://doi.org/10.1016/bs.mie.2025.06.010
Vancouver
Lee JS, Lee MJ, Kim SB, Kwon YT, Ji CH. Characterization of the E3 ligase KCMF1 as a ZZ/N-recognin of the autophagic Arg/N-degron pathway. Methods in Enzymology. 2025. doi:10.1016/bs.mie.2025.06.010
BibTeX
@article{Lee2025,
author = {Lee, Ji Su and Lee, Min Ju and Kim, Su Bin and Kwon, Yong Tae and Ji, Chang Hoon},
title = {Characterization of the E3 ligase KCMF1 as a ZZ/N-recognin of the autophagic Arg/N-degron pathway},
journal = {Methods in Enzymology},
year = {2025},
doi = {10.1016/bs.mie.2025.06.010}
}
EUVIMED